Catalyst Dossier · compiled by CeliA 🧫

Cara Therapeutics, Inc. (CARA)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
difelikefalin 2.0 mg	Phase 2	Pruritus
CR845 0.5 mcg/kg	Phase 3	Uremic Pruritus
CR845 0.25 mg Oral Tablet	Phase 2	Chronic Kidney Diseases
CR845 0.25 mg	Phase 2	Osteoarthritis
CR845 IV 1 mcg/kg	Phase 3	Post Abdominal Surgery Pain
CR845 tablet 1 mg	Phase 2	Osteoarthritis, Hip
difelikefalin 0.25 mg	Phase 2	Pruritus
CR845 1 mcg/kg	Phase 3	Uremic Pruritus
CR845	Phase 3	Postoperative Pain
Part A: CR845 0.5 mcg/kg	Phase 2	Pruritus

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CARA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.